FTC to Sue Drug Managers Over Insulin Prices

The Federal Trade Commission is preparing to sue three major pharmacy-benefit managers over their pricing negotiation tactics for drugs, including insulin. This comes after a two-year investigation into allegations that these companies steer patients away from lower-cost medications. The FTC plans to file lawsuits targeting the business practices associated with rebates brokered with drug manufacturers. Additionally, the agency is looking into the role of insulin manufacturers in these negotiations.

The Federal Trade Commission is planning to take legal action against the three largest pharmacy-benefit managers for their practices in negotiating drug prices, particularly for insulin. The FTC’s investigation, which spanned two years, looked into allegations that these companies manipulate patient choices to favor more expensive medications. The agency intends to file lawsuits specifically addressing the rebates they facilitate with drug manufacturers. Additionally, the FTC is examining the involvement of insulin manufacturers in these negotiations.